PURE's SDC-Based Food Safety Solutions Strategy Gains Traction -- Initial Orders From Three Food Processors

Marketwired

SAN DIEGO, CA--(Marketwired - Jan 16, 2014) - PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced continued progress on its strategic positioning as a food safety solution which was launched this past Fall.

  • PURE Hard Surface, an SDC-based antimicrobial disinfectant for food contact surfaces, has been proven to show superior efficacy as a safe, non-toxic product. Following extensive in plant testing of the product, PURE has received initial orders from three national food processors. The product continues to be tested at a number of other leading food processors where initial results have been very positive.

  • In addition, PURE is completing the final stage of testing its food safety solution in a leading quick service restaurant chain. Third party validated test results to-date have consistently shown use of PURE resulting in 90% + greater effectiveness in the reduction of bacteria and, hence, food safety risk.

  • These companies are part of PURE's previously disclosed customer pipeline of 25 national food companies which represent a potential annualized revenue stream of $20 - $30 million if fully rolled out.

"The successful testing and rapid acceptance of PURE as a superior food safety solution for food processors is an important step forward in the implementation of our business plan and bodes well for the additional food processors in our pipeline." said Hank Lambert, Chief Executive Officer of PURE Bioscience. "Gaining this initial traction with processors, combined with the prospects we see for restaurant chains, serves as strong validation for our strategic positioning of SDC for the food industry."

About PURE Bioscience, Inc.

PURE Bioscience, Inc. is focused on developing and commercializing its proprietary antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control within the food industry. The Company's technology platform is based on patented stabilized ionic silver, and its initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection. As a platform technology, SDC is distinguished from existing products in the marketplace by its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.

Forward-looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company's cash position and liquidity requirements, the Company's failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, including to manufacture its products, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission, including our annual report on Form 10-K filed October 24, 2013. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Contact:

Tom Hemingway
Redwood Investment Group
714-978-4425
Email Contact

Terri MacInnis
Director of IR
Bibicoff + MacInnis, Inc.
818-379-8500
Email Contact

Company
Peter C. Wulff
CFO & COO
PURE Bioscience, Inc.
619-596-8600 ext.111
Email Contact
View Comments (0)